{"id":31962,"date":"2020-03-31T17:57:40","date_gmt":"2020-03-31T15:57:40","guid":{"rendered":"https:\/\/wordpress-783423-2671269.cloudwaysapps.com\/?p=31962"},"modified":"2025-01-29T14:03:50","modified_gmt":"2025-01-29T13:03:50","slug":"march-31-2020-dermapharm-successfully-acquires-allergopharma","status":"publish","type":"post","link":"https:\/\/www.cometis.de\/en\/march-31-2020-dermapharm-successfully-acquires-allergopharma\/","title":{"rendered":"March 31, 2020<\/span> | Dermapharm successfully acquires Allergopharma"},"content":{"rendered":"

Corporate news<\/h1>\n

to the archive<\/a><\/p>\n

Dermapharm successfully acquires Allergopharma<\/h1>\n

 <\/p>\n

Gr\u00fcnwald, March 31, 2020 – Dermapharm Holding SE (\u201cDermapharm\u201d), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas, successfully completes its acquisition of Allergopharma.<\/p>\n

This Tuesday, March 31, 2020, saw the closing of the acquisition of Allergopharma GmbH & Co. KG, based in Reinbek near Hamburg, by Dermapharm Beteiligungs GmbH. The purchase contract already concluded on February 19, 2020, was subject to the approval of the relevant supervisory authorities. The transfer of Allergopharma\u2019s business in China is expected in the second half of 2020.<\/p>\n

Allergopharma specializes in the subcutaneous hyposensitization of allergies and offers a wide range of high-dose hypoallergenic preparations, so-called allergoids, as well as a large selection of allergens for diagnostics.<\/p>\n

\u201cWith Allergopharma, we are expanding our expertise in immunotherapy for the treatment of allergies and further developing our therapeutic area of dermatology,\u201d commented Dr Hans-Georg Feldmeier, Chairman of the Management Board of Dermapharm Holding SE.<\/p>\n

The contracting parties have agreed not to disclose the purchase price.<\/p>\n

Company profile: <\/strong><\/p>\n

Dermapharm – Pharmaceutical Excellence “Made in Germany”<\/p>\n

Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Gr\u00fcnwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company’s integrated business model comprises in-house development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a medical and pharmaceutical sales force. Dermapharm has more than 250 active pharmaceutical ingredients for more than 900 marketing authorisations (Arzneimittelzulassungen), which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. This assortment makes the company unique. In addition to Germany, the company’s core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm’s business model also includes a parallel import business, which operates under the “axicorp” brand. Based on revenues, Dermapharm was among the top five parallel import companies in Germany in 2019. In the “Herbal Extracts” segment, Dermapharm has access to the growth market for herbal pharmaceuticals through the Spanish company Euromed S.A., one of the leading manufacturers of herbal extracts and natural active ingredients.<\/p>\n

With a consistent R&D strategy and numerous successful product and company acquisitions over the past 25 years, Dermapharm has continuously optimised its business and provided external growth impulses in addition to organic growth. Dermapharm intends to continue on this profitable growth course in the future. The company is focusing on a three-pillar strategy: in-house development of new products, increase of its international footprint and further acquisitions.<\/p>\n

Contacts:<\/p>\n

Investor Relations & Corporate Communications
\nBritta Hamberger
\nPhone: +49 (0)89 \u2013 64186-233
\nFax: +49 (0)89 \u2013 64186-165
\ne-mail: ir@dermapharm.com<\/p>\n

cometis AG
\nClaudius Krause
\nPhone: +49 (0)611 \u2013 205855-28
\nFax: +49 (0)611 \u2013 205855-66
\ne-mail: ir@dermapharm.com<\/p>\n

Post as PDF<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Corporate news to the archive Dermapharm successfully acquires Allergopharma   Gr\u00fcnwald, March 31, 2020 – Dermapharm Holding SE (\u201cDermapharm\u201d), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas, successfully completes its acquisition of Allergopharma. This Tuesday, March 31, 2020, saw the closing of the acquisition of Allergopharma GmbH & Co. KG, based in […]<\/p>\n","protected":false},"author":2,"featured_media":98872,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[215,90],"tags":[276],"class_list":["post-31962","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dermapharm-corporate-news-en","category-news-en","tag-2020-2"],"acf":[],"yoast_head":"\nMarch 31, 2020 | Dermapharm successfully acquires Allergopharma - cometis AG<\/title>\n<meta name=\"description\" content=\"Dermapharm Holding SE (\u201cDermapharm\u201d), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas, successfully completes its acquisition of Allergopharma.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cometis.de\/en\/march-31-2020-dermapharm-successfully-acquires-allergopharma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"March 31, 2020 | Dermapharm successfully acquires Allergopharma\" \/>\n<meta property=\"og:description\" content=\"Dermapharm Holding SE (\u201cDermapharm\u201d), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas, successfully completes its acquisition of Allergopharma.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cometis.de\/en\/march-31-2020-dermapharm-successfully-acquires-allergopharma\/\" \/>\n<meta property=\"og:site_name\" content=\"cometis AG\" \/>\n<meta property=\"article:published_time\" content=\"2020-03-31T15:57:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-29T13:03:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"171\" \/>\n\t<meta property=\"og:image:height\" content=\"31\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Assistenz cometis AG\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Assistenz cometis AG\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/march-31-2020-dermapharm-successfully-acquires-allergopharma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/march-31-2020-dermapharm-successfully-acquires-allergopharma\\\/\"},\"author\":{\"name\":\"Assistenz cometis AG\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/person\\\/5359bae3178840cd846706150aa69cd1\"},\"headline\":\"March 31, 2020 | Dermapharm successfully acquires Allergopharma\",\"datePublished\":\"2020-03-31T15:57:40+00:00\",\"dateModified\":\"2025-01-29T13:03:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/march-31-2020-dermapharm-successfully-acquires-allergopharma\\\/\"},\"wordCount\":461,\"publisher\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/march-31-2020-dermapharm-successfully-acquires-allergopharma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"keywords\":[\"2020\"],\"articleSection\":[\"Dermapharm Corporate News\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/march-31-2020-dermapharm-successfully-acquires-allergopharma\\\/\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/march-31-2020-dermapharm-successfully-acquires-allergopharma\\\/\",\"name\":\"March 31, 2020 | Dermapharm successfully acquires Allergopharma - cometis AG\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/march-31-2020-dermapharm-successfully-acquires-allergopharma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/march-31-2020-dermapharm-successfully-acquires-allergopharma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"datePublished\":\"2020-03-31T15:57:40+00:00\",\"dateModified\":\"2025-01-29T13:03:50+00:00\",\"description\":\"Dermapharm Holding SE (\u201cDermapharm\u201d), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas, successfully completes its acquisition of Allergopharma.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/march-31-2020-dermapharm-successfully-acquires-allergopharma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cometis.de\\\/en\\\/march-31-2020-dermapharm-successfully-acquires-allergopharma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/march-31-2020-dermapharm-successfully-acquires-allergopharma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"contentUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"width\":172,\"height\":172},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/march-31-2020-dermapharm-successfully-acquires-allergopharma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"2019\",\"item\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/tag\\\/2019-2\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"March 31, 2020 | Dermapharm successfully acquires Allergopharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/\",\"name\":\"cometis AG\",\"description\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#organization\",\"name\":\"cometis AG\",\"alternateName\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2024\\\/12-old\\\/Cometis-Mobile-Logo-1.png\",\"contentUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2024\\\/12-old\\\/Cometis-Mobile-Logo-1.png\",\"width\":171,\"height\":31,\"caption\":\"cometis AG\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/cometis-ag\\\/\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/cometisAG\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/person\\\/5359bae3178840cd846706150aa69cd1\",\"name\":\"Assistenz cometis AG\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g\",\"caption\":\"Assistenz cometis AG\"},\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/author\\\/assistenz-cometis-ag\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"March 31, 2020 | Dermapharm successfully acquires Allergopharma - cometis AG","description":"Dermapharm Holding SE (\u201cDermapharm\u201d), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas, successfully completes its acquisition of Allergopharma.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cometis.de\/en\/march-31-2020-dermapharm-successfully-acquires-allergopharma\/","og_locale":"en_US","og_type":"article","og_title":"March 31, 2020 | Dermapharm successfully acquires Allergopharma","og_description":"Dermapharm Holding SE (\u201cDermapharm\u201d), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas, successfully completes its acquisition of Allergopharma.","og_url":"https:\/\/www.cometis.de\/en\/march-31-2020-dermapharm-successfully-acquires-allergopharma\/","og_site_name":"cometis AG","article_published_time":"2020-03-31T15:57:40+00:00","article_modified_time":"2025-01-29T13:03:50+00:00","og_image":[{"width":171,"height":31,"url":"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png","type":"image\/png"}],"author":"Assistenz cometis AG","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Assistenz cometis AG","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cometis.de\/en\/march-31-2020-dermapharm-successfully-acquires-allergopharma\/#article","isPartOf":{"@id":"https:\/\/www.cometis.de\/en\/march-31-2020-dermapharm-successfully-acquires-allergopharma\/"},"author":{"name":"Assistenz cometis AG","@id":"https:\/\/www.cometis.de\/en\/#\/schema\/person\/5359bae3178840cd846706150aa69cd1"},"headline":"March 31, 2020 | Dermapharm successfully acquires Allergopharma","datePublished":"2020-03-31T15:57:40+00:00","dateModified":"2025-01-29T13:03:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cometis.de\/en\/march-31-2020-dermapharm-successfully-acquires-allergopharma\/"},"wordCount":461,"publisher":{"@id":"https:\/\/www.cometis.de\/en\/#organization"},"image":{"@id":"https:\/\/www.cometis.de\/en\/march-31-2020-dermapharm-successfully-acquires-allergopharma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","keywords":["2020"],"articleSection":["Dermapharm Corporate News","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.cometis.de\/en\/march-31-2020-dermapharm-successfully-acquires-allergopharma\/","url":"https:\/\/www.cometis.de\/en\/march-31-2020-dermapharm-successfully-acquires-allergopharma\/","name":"March 31, 2020 | Dermapharm successfully acquires Allergopharma - cometis AG","isPartOf":{"@id":"https:\/\/www.cometis.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cometis.de\/en\/march-31-2020-dermapharm-successfully-acquires-allergopharma\/#primaryimage"},"image":{"@id":"https:\/\/www.cometis.de\/en\/march-31-2020-dermapharm-successfully-acquires-allergopharma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","datePublished":"2020-03-31T15:57:40+00:00","dateModified":"2025-01-29T13:03:50+00:00","description":"Dermapharm Holding SE (\u201cDermapharm\u201d), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas, successfully completes its acquisition of Allergopharma.","breadcrumb":{"@id":"https:\/\/www.cometis.de\/en\/march-31-2020-dermapharm-successfully-acquires-allergopharma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cometis.de\/en\/march-31-2020-dermapharm-successfully-acquires-allergopharma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cometis.de\/en\/march-31-2020-dermapharm-successfully-acquires-allergopharma\/#primaryimage","url":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","contentUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","width":172,"height":172},{"@type":"BreadcrumbList","@id":"https:\/\/www.cometis.de\/en\/march-31-2020-dermapharm-successfully-acquires-allergopharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cometis.de\/en\/"},{"@type":"ListItem","position":2,"name":"2019","item":"https:\/\/www.cometis.de\/en\/tag\/2019-2\/"},{"@type":"ListItem","position":3,"name":"March 31, 2020 | Dermapharm successfully acquires Allergopharma"}]},{"@type":"WebSite","@id":"https:\/\/www.cometis.de\/en\/#website","url":"https:\/\/www.cometis.de\/en\/","name":"cometis AG","description":"Deutschlands f\u00fchrende Investor Relations Agentur","publisher":{"@id":"https:\/\/www.cometis.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cometis.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.cometis.de\/en\/#organization","name":"cometis AG","alternateName":"Deutschlands f\u00fchrende Investor Relations Agentur","url":"https:\/\/www.cometis.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cometis.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png","contentUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png","width":171,"height":31,"caption":"cometis AG"},"image":{"@id":"https:\/\/www.cometis.de\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/cometis-ag\/","https:\/\/www.youtube.com\/user\/cometisAG"]},{"@type":"Person","@id":"https:\/\/www.cometis.de\/en\/#\/schema\/person\/5359bae3178840cd846706150aa69cd1","name":"Assistenz cometis AG","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g","caption":"Assistenz cometis AG"},"url":"https:\/\/www.cometis.de\/en\/author\/assistenz-cometis-ag\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/posts\/31962","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/comments?post=31962"}],"version-history":[{"count":0,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/posts\/31962\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/media\/98872"}],"wp:attachment":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/media?parent=31962"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/categories?post=31962"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/tags?post=31962"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}